Company Profile

Bioinvision Inc
Profile last edited on: 11/21/2019      CAGE: 47ZU6      UEI: DPL8U7UN1435

Business Identifier: Mouse-sized specimins celllar sensitivity
Year Founded
2005
First Award
2006
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

781 Beta Drive Suite E
Cleveland, OH 44143
   (216) 310-0302
   inquiry@bioinvision.com
   www.bioinvision.com
Location: Single
Congr. District: 11
County: Cuyahoga

Public Profile

With the technology underpinning firm's work originally developed at Case Western Reserve University and licensed exclusively to the small firm, BioInVision brings its expertise in high-resolution, large field-of-view microscopic imaging, 3D reconstruction, and specialized image processing and analysis capabilities. Data sizes for many applications routinely exceed 60GB and specialized hardware and software has been developed to provide a rich multi-scale interactive visualization experience to the user. BioInVision's core competency in cryo-imaging underpins efforts to develop applications and algorithms for the pre-clinical market, being used to grow applications of cryo-imaging in stem cells, toxicology, and nanoparticle imaging agent/drug delivery. Application areas of CryoViz imaging include: Stem Cells, Cancer, Molecular Imaging, Gene Expression Imaging, Developmental Biology, Toxicology, Biomarker Validation and Anatomical Phenotyping

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $224,207
Project Title: Whole-Organism, Real-time Decision-enabled 3D Tissue Imaging and Recovery for Molecular Analysis
2022 2 NIH $2,192,336
Project Title: System-Independent Quantitative Cardiac Ct Perfusion
2019 2 NIH $1,870,680
Project Title: Cancer Imaging and Therapy Platform
2010 1 NIH $248,300
Project Title: In Vivo Assessment of Embryonic Stem Cell Teratoma Prevention
2009 1 NIH $196,614
Project Title: Imaging In Developmental Toxicology

Key People / Management

  Debashish Roy -- President and CEO

  David L Wilson -- Founder and CTO

  Madhusudhana Gargesha -- Vice President, Research and Operations

  Horst Von Recum